Location History:
- Wiltshire, GB (2014 - 2015)
- Salisbury, GB (2017 - 2020)
- Histon, GB (2018 - 2021)
- Cambridge, GB (2018 - 2023)
Company Filing History:
9 out of 66 
8 out of 48 
3 out of 846 
Years Active: 2014-2023
Title: The Innovative Contributions of Colin Stott to Cannabinoid Research
Introduction
Colin Stott, an accomplished inventor based in Salisbury, GB, has made significant strides in the field of cannabinoid research. With a remarkable portfolio of 17 patents, he has dedicated his efforts toward finding innovative solutions for the treatment of epilepsy through the use of cannabinoids.
Latest Patents
Among his latest patents are groundbreaking inventions related to the use of 7-hydroxy-cannabidiol (7-OH-CBD) and 7-hydroxy-cannabidivarin (7-OH-CBDV) for epilepsy treatment. His inventions highlight the use of these cannabinoid metabolites, which can either be extracted in a highly purified form from plants or reproduced synthetically. Additionally, he has developed a patent concerning the use of cannabidiolic acid (CBDA) in treating generalized seizures, particularly tonic-clonic seizures. This invention emphasizes a botanical drug substance where the CBDA concentration exceeds 60%, preferably achieving over 95%, and ensuring the removal of other components such as tetrahydrocannabinol (THC).
Career Highlights
Throughout his illustrious career, Colin Stott has worked with notable companies in the cannabis research sector, namely GW Pharmaceutical Limited and GW Research Limited. His contributions have not only advanced the scientific understanding of cannabinoids but have also provided innovative treatment options for patients suffering from epilepsy.
Collaborations
Colin Stott has collaborated with prominent figures in the field, including Vincenzo Di Marzo and Geoffrey W. Guy. These partnerships have fostered a creative environment for research and development, driving forward advancements that improve the therapeutic application of cannabinoids in medicine.
Conclusion
Colin Stott's innovation in cannabinoid research has the potential to transform treatment options for epilepsy. His extensive patent portfolio and collaborations with esteemed professionals underscore his vital role in the ongoing exploration of the medicinal properties of cannabinoids. As research continues to unfold, his contributions remain pivotal in shaping the future of epilepsy treatment.